论著

儿童肺炎支原体肺炎进展为塑型性支气管炎的危险因素

  • 李莉 ,
  • 孔程祥 ,
  • 闫睿 ,
  • 许锦姬
展开
  • 深圳市宝安区妇幼保健院儿科,广东 深圳 518102
许锦姬,副主任医师,研究方向:儿童呼吸系统疾病,E-mail:

李莉,主治医师,研究方向:儿童呼吸系统疾病,E-mail:

Copy editor: 郑巧兰

收稿日期: 2024-09-22

  网络出版日期: 2025-04-23

基金资助

国家自然科学基金(82101804)

深圳市宝安区医疗卫生基础研究项目(2020JD036)

深圳市宝安区引进高层次医学团队项目(202404)

Risk factors of the progression of Mycoplasma pneumoniae pneumonia into plastic bronchitis in children

  • LI Li ,
  • KONG Chengxiang ,
  • YAN Rui ,
  • XU Jinji
Expand
  • Department of Pediatrics, Shenzhen Baoan Women's and Children's Hospital, Shenzhen 518102, China
XU Jinji, E-mail:

Received date: 2024-09-22

  Online published: 2025-04-23

摘要

目的 分析肺炎支原体肺炎 (MPP) 进展为塑型性支气管炎 (PB) 患儿的临床特点,并探讨其危险因素。方法 选取387例行支气管镜检查的MPP患儿,按照镜下是否有塑型性支气管管型形成分为MPP进展PB组和MPP组,比较2组的特征差异,分析患儿进展为PB的危险因素。结果 MPP进展PB组影像学改变(表现为肺不张、肺坏死、大量胸腔积液、支气管狭窄或闭塞)的比例、混合感染率、中性粒细胞百分比、淋巴细胞百分比、中性粒细胞与淋巴细胞比率 (NLR)、降钙素原、C-反应蛋白、乳酸脱氢酶(LDH)水平均高于MPP组(均P < 0.05)。多因素Logistic回归分析显示,NLR>3.15 ng/L [OR(95%CI)=2.084(1.155,3.759)]、LDH>408.5 U/L [OR(95%CI)= 3.469(1.797,6.696)]、影像学改变[OR(95%CI)=2.707(1.241,5.907)]及混合感染[OR(95%CI)=4.517(2.201,9.271)]是MPP进展为PB的独立危险因素。结论 特征性影像学改变、混合感染、较高的LDH和NLR是MPP进展为PB的危险因素,临床医师早期识别这些因素有助于尽早进行干预。

本文引用格式

李莉 , 孔程祥 , 闫睿 , 许锦姬 . 儿童肺炎支原体肺炎进展为塑型性支气管炎的危险因素[J]. 新医学, 2025 , 56(4) : 379 -385 . DOI: 10.12464/j.issn.0253-9802.2024-0388

Abstract

Objective To analyze the clinical characteristics of children with Mycoplasma pneumoniae pneumonia (MPP) who progress into plastic bronchitis (PB) and identify the associated risk factors. Methods A total of 387 children diagnosed with MPP who underwent bronchoscopy were included in the study. They were divided into the MPP progressing into PB group and the MPP group based on the presence of plastic bronchial casts observed under microscopy. Clinical characteristics between two groups were compared, and the risk factors of the progression into PB were analyzed. Results The imaging findings, particularly from chest CT scans, revealed a higher incidence of atelectasis, lung necrosis, massive pleural effusion, bronchial stenosis or bronchial occlusion in the MPP progressing to PB group. Similarly, the occurrence of mixed infections, the levels of neutrophil percentage, lymphocyte percentage, neutrophil-to-lymphocyte ratio (NLR), procalcitonin, C-reactive protein and lactate dehydrogenase (LDH) in the MPP progressing into PB group were significantly higher than those in the MPP group (all P < 0.05). Multivariate logistic regression analysis demonstrated that NLR >3.15 ng/L [OR (95% CI) =2.084 (1.155, 3.759)], LDH levels >408.5 U/L [OR (95% CI) =3.469 (1.797, 6.696)], imaging changes [OR (95% CI) =2.707 (1.241, 5.907)], and mixed infections [OR (95% CI) =4.517 (2.201, 9.271)] were the independent risk factors of MPP progressing into PB. Conclusions Characteristic imaging changes, mixed infections, and elevated levels of LDH and NLR are the independent risk factors for the progression of MPP into PB. Early identification of these factors by clinicians can enable prompt intervention.

肺炎支原体(Mycoplasma pneumoniae,MP)是引起儿童社区获得性肺炎(community acquired pneumonia,CAP)最常见的病原体之一,大约3%~10%的儿童呼吸道感染由MP引起[1],MP肺炎(Mycoplasma pneumoniae pneumonia,MPP)占住院儿童CAP的10%~40%[2]。塑型性支气管炎(plastic bronchitis,PB)是一种内源性异物局部或广泛阻塞支气管,导致肺部分或完全通气功能障碍的疾病[3]。感染引起的PB临床表现包括反复发热、呼吸急促,并可迅速进展为急性呼吸困难和呼吸衰竭,甚至危及生命的呼吸和循环衰竭,支气管镜去除塑型后可迅速缓解[4-6]。MPP引起PB的报道逐渐增多[7],其次是由病毒和细菌引起的PB,其中病毒主要为流感病毒和腺病毒[8]。目前,呼吸道感染导致PB的机制尚不完全清楚,但文献报道涉及3个方面:炎症细胞浸润和炎症介质释放,炎症介质引起呼吸道黏液分泌增加并难以清除,气道炎症增加淋巴管通透性并促进管型的形成[9-10]。PB的发生增加了MPP治疗的难度,因此,早期识别PB并尽早完善支气管镜检查,取出塑型物,保持呼吸道通畅,对于促进疾病恢复至关重要。
全血细胞计数是一种简单、快速且廉价的检查。白细胞计数、中性粒细胞水平、淋巴细胞水平、C反应蛋白(C-reactive protein,CRP)等通常用作炎症标志物和疾病严重程度的指标。中性粒细胞与淋巴细胞比率(neutrophil to lymphocyte ratio,NLR)是系统性红斑狼疮、阑尾炎、溃疡性结肠炎和恶性肿瘤等疾病的可靠炎症标志物[11-12]。已有研究表明,NLR在重症MPP的诊断中有较高的灵敏度和特异度,并可作为预测难治性MPP不良预后的系统性炎症生物标志物[13-14]。NLR、中性粒细胞水平和CRP均为难治性MPP的独立危险因素,其中NLR的相对危险程度最高,NLR升高与中性粒细胞增加及淋巴细胞减少密切相关[15]。本研究拟通过对MPP进展PB与未进展PB患者的临床特征、NLR、炎症指标、影像学结果及混合感染情况进行分析,探索MPP进展为PB的危险因素,旨在为PB的早期诊疗提供参考。

1 对象与方法

1.1 研究对象

选取2023年1月至12月在深圳市宝安区妇幼保健院儿科病房行纤维支气管镜检查的MPP患儿,按照镜下是否有塑型性支气管管型形成,分为MPP进展PB组和MPP组。纳入标准:①1个月至14岁的肺炎住院患儿;②儿童MPP、重症和危重症MPP诊断符合《儿童肺炎支原体肺炎诊疗指南(2023年版)》中的诊断标准[16],MPP符合MP感染肺炎的临床和影像学表现,并且满足肺泡灌洗液MP-DNA阳性;③符合PB诊断标准,经支气管镜取出树枝样、条状置于生理盐水中呈质韧的塑型物[17];④符合纤维支气管镜的适应证且行相关检查[18-19]。排除标准:①既往复发性呼吸道感染、哮喘、慢性肺病、心脏病手术后、严重血液系统疾病或免疫缺陷病;②吸入型异物;③住院数据不完整。本研究获深圳市宝安区妇幼保健院医学伦理委员会批准(批件号:LLSC2024-01-04-18-KS),因本研究为回顾性分析既往临床诊疗记录资料,豁免知情同意。

1.2 数据收集

收集2组患儿性别、年龄、身高、体质量、纤维支气管镜检查前病程、入院前抗生素使用情况、入院后实验室检查结果[白细胞(white blood cell,WBC)、血红蛋白(haemoglobin,HB)、血小板(platelet,PLT)、中性粒细胞计数(neutrophil count,N)、淋巴细胞计数(lymphocyte count,L)、中性粒细胞百分比(neutrophil percentage,N%)、淋巴细胞百分比(lymphocyte percentage,L%)、NLR]、炎症指标[CRP、降钙素原(procalcitonin,PCT)]、乳酸脱氢酶(lactate dehydrogenase,LDH)、混合感染(通过检测鼻咽拭子、肺泡灌洗液、痰、血液等明确合并病毒或细菌感染)情况、影像学改变(胸部CT表现为肺不张、肺坏死、大量胸腔积液、支气管狭窄或闭塞)及纤维支气管镜检查结果等。

1.3 统计学方法

统计分析采用SPSS 26.0。正态分布的连续型变量以$\bar{x}\pm s$表示,2组间比较采用独立样本t检验;非正态分布的连续型变量用M(P25,P75)表示,2组间比较采用Mann-Whitney U检验;计数资料用n(%)表示,组间比较行χ 2检验或Fisher精确检验;连续型变量同时采用受试者操作特征(receiver operating characteristic,ROC)曲线进行分析,根据最佳截断值,转成分类变量;将差异有统计学意义的变量纳入多因素Logistic回归分析。以双侧P < 0.05为差异有统计学意义。

2 结果

2.1 2组患儿基本情况

共纳入387例MPP患儿,其中MPP进展PB组67例(17.3%),MPP组320例(82.7%),2组患儿年龄、身高、体质量、性别构成、入院前抗生素使用患者占比、抗生素使用种类(除多西环素外)、是否使用2种及以上抗生素、入院前病程差异对比均无统计学意义(均P > 0.05)。其中,2组多西环素使用率虽有统计学差异,但比例均较低。MP进展PB组重症患儿和危重症患儿占比均高于对照组(均P < 0.001),见表1
表1 MPP进展PB组与MPP组患儿基本资料比较

Table 1 Comparison of basic data between MPP progressing into PB group and MPP group

变 量 MPP进展PB组(n=67) MPP组(n=320) t/χ 2 P
年龄/月 85.2±30.9 80.3±29.5 1.178 0.242
身高/cm 124.6±19.4 120.3±18.1 1.519 0.133
体质量/kg 24.5±10.5 22.8±8.6 1.194 0.236
男性/n(%) 42(62.7) 164(51.2) 2.911 0.088
入院前抗生素使用/n(%) 64(95.5) 298(93.1) 0.527 0.468
抗生素使用种类/n(%)
大环内酯类 44(65.7) 222(69.4) 0.354 0.552
头孢类 45(67.2) 242(75.6) 2.070 0.150
青霉素类 7(10.4) 34(10.6) 0.002 0.966
多西环素 3(4.5) 1(0.3) 0.017a
其他b 1(1.5) 2(0.6) 0.436a
入院前使用2种及以上抗生素/n(%) 28(45.9) 177(56.7) 2.417 0.120
入院前病程/d 6.6±2.6 6.8±2.4 -0.723 0.470
重症患儿/n(%) 67(100.0) 267(83.4) <0.001
危重症患儿/n(%) 6(9.0) 0(0) <0.001

注:a采用Fisher精确检验;b克林霉素、庆大霉素。

2.2 MPP进展PB组患儿纤维支气管镜下塑型物分布特点

纤维支气管镜下可见痰栓堵塞管口,吸出白色或黄白色树枝样塑型物,堵塞部位以累及2个及以上肺叶最多见,占比64.2%,其次是右下叶,占比11.9%,见表2
表2 MPP进展PB患儿塑型物分布特点

Table 2 Characteristics of bronchial cast distribution in MPP patients progressing into PB

塑型物分布 n 占比/%
左上叶 4 6.0
左下叶 6 8.9
右上叶 5 7.5
右中叶 1 1.5
右下叶 8 11.9
≥2个肺叶 43 64.2

2.3 MPP进展PB组与MPP组患儿混合感染情况比较

MPP进展PB组混合感染率高于MPP组[21例(31.3%)vs. 24例(7.5%),P < 0.001],见表3。21例MPP进展PB患儿中,11例为病毒感染(腺病毒9例、甲型流感病毒1例、副流感病毒Ⅲ1例),13例为细菌感染(流感嗜血杆菌4例、肺炎链球菌2例、金黄色葡萄球菌2例、铜绿假单胞菌2例、百日咳鲍特杆菌1例、化脓性链球菌1例、阴沟肠杆菌1例),其中3例为细菌病毒混合感染,均为细菌合并腺病毒感染。
表3 MPP进展PB组与MPP组患儿混合感染情况比较

Table 3 Comparison of mixed infection status between MPP progressing into PB group and MPP group

变 量 MPP进展PB组(n=67) MPP组(n=320) χ 2 P
混合感染/n(%) 21(31.3) 24(7.5) 30.65 <0.001
病毒/n(%) 11(16.4) 13(4.1) 14.53 <0.001
细菌/n(%) 13(19.4) 12(3.8) 22.46 <0.001

2.4 MPP进展PB组与MPP组患儿影像学改变情况比较

MPP进展PB组胸部CT表现为肺不张、肺坏死、大量胸腔积液、支气管狭窄或闭塞15例(22.4%),MPP组30例(9.4%),差异有统计学意义(P = 0.002)。15例MPP进展PB患儿中,肺不张8例(其中4例进展支气管闭塞),支气管闭塞3例,坏死性肺炎2例,大量胸腔积液1例,支气管狭窄1例。

2.5 MPP进展PB组与MPP组患儿实验室检查结果比较

2组患儿实验室检查结果如WBC、HB、PLT、N、L差异均无统计学意义(均P > 0.05)。N%、L%、NLR、PCT、CRP、LDH等差异均有统计学意义,利用ROC曲线下面积最大时对应的cutoff值将NLR、PCT、CRP、LDH转变为二分类变量后进行2组比较。见表4
表4 MPP进展PB组与MPP组患儿实验室检查结果比较

Table 4 Comparison of the laboratory test results between MPP progressing into PB group and MPP group

变 量 MPP进展PB组(n=67) MPP组(n=320) Z/ χ 2/t P
WBC/(×109/L) 6.9(5.7,10.4) 6.9(5.5,8.4) -0.839 0.401
HB/(g/L) 120(114,126) 122(115,127) -0.823 0.411
PLT/(×109/L) 256(212,354) 277(230,338) -1.055 0.291
N%/% 66.5(57.0,75.0) 63.0(56.0,69.0) -2.378 0.017
L%/% 23.3(17.0,31.0) 27.0(21.0,33.0) -2.726 0.006
NLR 2.87(1.77,4.33) 2.31(1.66,3.18) -2.642 0.008
NLR>3.15/n(%) 31(46.3) 85(26.5) 10.25 0.001
N/(×109/L) 4.4(3.4,6.8) 4.2(3.4,5.4) -1.561 0.119
L/(×109/L) 1.6(1.2,2.4) 1.8(1.4,2.4) -1.690 0.091
PCT/(ng/L) 0.54±1.24 0.17±0.43 4.295 <0.001
PCT>0.17(ng/L)/n(%) 31(46.3) 58(18.1) 24.779 <0.001
LDH/(U/L) 352(267,509) 303(263,352) -3.650 <0.001
LDH>408.5(U/L)/n(%) 25(37.3) 34(10.6) 30.539 <0.001
CRP/(mg/L) 47.9±73.0 23.1±21.9 5.112 <0.001
CRP>21.3(mg/L)/n(%) 38(56.7) 114(35.6) 10.333 0.001

2.6 MPP进展PB的多因素分析

以MPP是否进展PB为因变量,混合感染情况、影像学改变以及实验室检查结果中差异有统计学意义的变量为自变量,进行多因素Logistic回归分析,变量赋值如下:有混合感染为1、无为0,有影像学改变(肺不张、肺坏死、中大量胸腔积液、支气管狭窄或闭塞为1,无为0;NLR≤3.15 ng/L为0,>3.15 ng/L为1;PCT≤0.17 ng/mL为0,>0.17 ng/mL为1;CRP≤21.3 mg/L为0,>21.3 mg/L为1;LDH≤408.5 U/L为0;>408.5 U/L为1。结果显示,NLR>3.15 ng/L、LDH>408.5 U/L、影像学改变及混合感染是MPP进展PB的独立危险因素,Hosmer-Lemeshow检验P = 0.542,说明Logistic回归模型拟合度较好。见表5
表5 MPP进展PB的多因素Logistic回归分析

Table 5 Multivariate Logistic regression analysis of MPP progressing into PB

变 量 β SE Wald P OR(95%CI)
NLR>3.15 ng/L 0.734 0.301 5.953 0.015 2.084(1.155,3.759)
LDH>408.5 U/L 1.244 0.336 13.736 <0.001 3.469(1.797,6.696)
影像学改变 0.996 0.398 6.244 0.012 2.707(1.241,5.907)
混合感染 1.508 0.367 16.897 <0.001 4.517(2.201,9.271)

3 讨论

PB是一种相对罕见的呼吸系统疾病,可导致严重的呼吸系统并发症,如呼吸衰竭和死亡[6]。研究表明,呼吸道感染是我国PB的主要病因,而MP是引起PB的主要致病菌[7,10]。本研究分析了PB患儿的塑型物分布特点,结果显示,以≥2个肺叶和右下叶最为多见,这与既往研究结果一致[17]。此外,我们对MPP进展为PB的危险因素进行了分析,结果显示,影像学改变、混合感染、LDH水平高于408.5 U/L、NLR高于3.15 ng/L是MPP进展为PB的独立危险因素。
实验室检测是一种简便实用的评估PB严重程度的方法。在本研究中,MPP进展PB组N%、NLR、CRP、PCT、LDH水平均升高,而L%水平降低,与既往研究一致[20-21]。既往研究显示,重症肺炎患者CRP和PCT的水平越高,病情越严重,且在死亡组中明显高于病情好转组[22]。NLR是神经内分泌应激和免疫炎症反应强度最合适、最简单、最可靠的参数,它能够很好地表达中性粒细胞(先天免疫系统)和淋巴细胞(适应性免疫系统)这2个基本免疫能力白细胞亚群之间的紧密功能关系。NLR的正常范围为1~2,成人NLR高于3.0或低于0.7均为病理性的。NLR 2.3~3.0为中间水平,可作为癌症、动脉粥样硬化、感染、炎症、精神疾病和压力等病理状态或过程的早期预警,并且NLR升高是细菌感染的预测指标[23]。此外,持续性淋巴细胞减少与重症患者的死亡率和继发感染增加有关[24-25]。已有研究发现,难治性MPP患儿与普通MPP患儿相比具有更高的NLR水平,并且高NLR患儿的坏死性肺炎发展得更早、发生率更高[26-27]。陆泳等[28]构建的MPP患儿发生PB的风险预测模型中,NLR是重要的预测因子,他们推测是中性粒细胞引起的强烈炎症反应引起淋巴细胞凋亡,从而导致NLR升高。尽管儿童与成人外周血白细胞分类水平不尽相同,但已有多个文献报道NLR在预测儿童不同病原感染肺炎中起到关键作用[29-30],一项回顾性研究显示NLR>3.92可能对6岁以上儿童的难治性MPP具有重要的预测价值[31]。在本研究中,NLR>3.15是PB的独立危险因素,说明PB患儿体内具有更激烈的炎症反应,NLR是预测PB的可靠因子。
LDH是一种广泛存在于各种重要器官中的细胞质酶,在能量代谢和氧化应激过程中发挥着重要作用。既往研究发现,MPP进展PB患者LDH水平较单纯难治性MPP患者明显升高,且LDH是PB有力的预测指标[32]。这与机体过度的免疫炎症反应导致大量炎症因子释放有关[33]。这些炎症因子进一步引起严重的气道黏膜损伤、清除功能障碍以及上皮细胞脱落,最终形成黏液栓并阻塞气道[34]。在本研究中,LDH亦被证实为PB的独立危险因素,与上述研究结果一致。此外,本研究还发现胸部CT表现为肺不张、肺坏死、大量胸腔积液、支气管狭窄或支气管闭塞的患儿,其发生PB的风险也增加,这与既往研究一致,表明MP诱导的PB病例的局部免疫应答比非PB病例更强烈[21]。有研究指出,与单纯MP感染相比,合并感染可导致难治性MPP患儿的疾病严重程度更高,且腺病毒感染是重症MPP的危险因素[35-36],相关研究报道,在难治性MPP肺炎中,合并细菌感染的比例明显升高,其中最常见的细菌是肺炎链球菌,其次是流感嗜血杆菌[37]。在本研究中,混合感染亦被发现是PB的预测指标之一,而位居首位的细菌是流感嗜血杆菌,这可能与不同地域流行细菌种类的差异有关。
本研究存在一些局限性。首先,这是一项单中心研究,结果可能受到特定医疗环境和患者群体的影响,未来需要开展多中心大样本研究进一步验证结果。此外,本研究为回顾性分析,可能存在选择偏倚等,影响结果的普遍性和准确性,未来可进一步开展前瞻性研究,优化风险预测模型,并探讨早期干预措施对PB发生率的影响。
综上所述,本研究引入了NLR作为MPP患儿发生PB的危险因素之一,并进行了多因素分析,获得了MPP进展为PB的4个独立危险因素,该4个因素在住院患者中均易于获取。该研究结果可以帮助临床医师早期识别MPP进展为PB的高危患者并及时进行干预,以降低疾病进展风险。
利益冲突声明:本研究未受到企业、公司等第三方资助,不存在潜在利益冲突。
[1]
LIU J, WANG M, ZHAO Z, et al. Viral and bacterial coinfection among hospitalized children with respiratory tract infections[J]. Am J Infect Contr, 2020, 48(10): 1231-1236. DOI: 10.1016/j.ajic.2020.01.013.

[2]
ZHONG H, YIN R, ZHAO R, et al. Analysis of clinical characteristics and risk factors of plastic bronchitis in children with Mycoplasma pneumoniae pneumonia[J]. Front Pediatr, 2021, 9: 735093. DOI: 10.3389/fped.2021.735093.

[3]
LI Y, WILLIAMS R J, DOMBROWSKI N D, et al. Current evaluation and management of plastic bronchitis in the pediatric population[J]. Int J Pediatr Otorhinolaryngol, 2020, 130: 109799. DOI: 10.1016/j.ijporl.2019.109799.

[4]
KUNDER R, KUNDER C, SUN H Y, et al. Pediatric plastic bronchitis: case report and retrospective comparative analysis of epidemiology and pathology[J]. Case Rep Pulmonol, 2013, 2013: 649365. DOI: 10.1155/2013/649365.

[5]
蔡霞, 孙静, 李伟. 8例重症塑型性支气管炎的临床分析[J]. 中华危重病急救医学, 2016, 28(1):73-75. DOI: 10.3760/cma.j.issn.2095-4352.2016.01.014.

CAI X, SUN J, LI W, et al. Clinical analysis of severe plastic bronchitis in 8 children[J]. Chin Crit Care Med, 2016, 28(1): 73-75. DOI: 10.3760/cma.j.issn.2095-4352.2016.01.014.

[6]
SOYER T, YALCIN Ş, EMIRALIOĞLU N, et al. Use of serial rigid bronchoscopy in the treatment of plastic bronchitis in children[J]. J Pediatr Surg, 2016, 51(10): 1640-1643. DOI: 10.1016/j.jpedsurg.2016.03.017.

PMID

[7]
HUANG J J, YANG X Q, ZHUO Z Q, et al. Clinical characteristics of plastic bronchitis in children: a retrospective analysis of 43 cases[J]. Respir Res, 2022, 23(1): 51. DOI: 10.1186/s12931-022-01975-1.

[8]
胡晓光, 张海邻. 儿童塑型性支气管炎的常见病因及致病机制[J]. 中华实用儿科临床杂志, 2021, 36(4): 244-247. DOI: 10.3760/cma.j.cn101070-20210113-00059.

HU X G, ZHANG H L. Common etiology and pathogenesis of plastic bronchitis in children[J]. Chin J Appl Clin Pediatr, 2021, 36(4): 244-247. DOI: 10.3760/cma.j.cn101070-20210113-00059.

[9]
YUAN L, HUANG J J, ZHU Q G, et al. Plastic bronchitis associated with adenovirus serotype 7 in children[J]. BMC Pediatr, 2020, 20(1): 268. DOI: 10.1186/s12887-020-02119-4.

[10]
WANG L, WANG W, SUN J M, et al. Efficacy of fiberoptic bronchoscopy and bronchoalveolar lavage in childhood-onset, complicated plastic bronchitis[J]. Pediatr Pulmonol, 2020, 55(11): 3088-3095. DOI: 10.1002/ppul.25016.

[11]
QIN B, MA N, TANG Q, et al. Neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) were useful markers in assessment of inflammatory response and disease activity in SLE patients[J]. Mod Rheumatol, 2016, 26(3): 372-376. DOI: 10.3109/14397595.2015.1091136.

PMID

[12]
TURHAN V B, GÖK H F, ÜNSAL A, et al. Pre-operative neutrophil/lymphocyte and platelet/lymphocyte ratios are effective in predicting complicated acute cholecystitis[J]. Ulus Travma Acil Cerrahi Derg, 2022, 28(4): 471-476. DOI: 10.14744/tjtes.2021.49956.

[13]
张芙荣, 周卫芳, 李玉琴, 等. 中性粒细胞与淋巴细胞比值、血小板与淋巴细胞比值在重症肺炎支原体肺炎中的诊断价值[J]. 中华实用儿科临床杂志, 2022, 37(4): 260-264. DOI: 10.3760/cma.j.cn101070-20201013-01612.

ZHANG F R, ZHOU W F, LI Y Q, et al. The diagnostic value of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio in severe Mycoplasma pneumoniae pneumonia[J]. Chin J Appl Clin Pediatr, 2022, 37(4): 260-264. DOI: 10.3760/cma.j.cn101070-20201013-01612.

[14]
邓如玉, 罗征秀. 儿童难治性肺炎支原体肺炎生物标志物研究进展[J]. 临床医学进展, 2024, 14(3): 200-205. DOI: 10.12677/ACM.2024.143685.

DENG R Y, LUO Z X. Research progress on biomarkers of refractory Mycoplasma pneumoniae pneumonia in children[J]. Advances in Clinical Medicine, 2024, 14(3): 200-205. DOI: 10.12677/acm.2024.143685.

[15]
苏国德, 彭效芹, 毕颖, 等. 中性粒细胞与淋巴细胞比值在儿童难治性肺炎支原体肺炎中的诊断及预测价值[J]. 徐州医科大学学报, 2022, 42(9): 672-676.DOI: 10.3969/i.issn.2096-3882.2022.09.010.

SU G D, PENG X Q, Bl Y, et al. Application of neutrophil/lymphocyte ratio in the diagnosis and prediction of refractory Mycoplasma pneumoniae pneumonia in children[J]. Journal of Xuzhou Medical University, 2022, 42(9): 672-676. DOI: 10.3969/j.issn.2096-3882.2022.09.010.

[16]
国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 全科医学临床与教育, 2023, 21(3): 196-202. DOI: 10.13558/j.cnki.issn1672-3686.2023.003.002.

National Health Commission of the People's Republic of China. Guidelines for Diagnosis and Treatment of Mycoplasma pneumonae pneumonia in Children (2023 Edition)[J]. Clin Educ Gen Pract, 2023, 21(3): 196-202. DOI: 10.13558/j.cnki.issn1672-3686.2023.003.002.

[17]
杨菊萍, 丁春杰, 陈静, 等. 小儿MPP并发塑型性支气管炎的临床特点、胸部CT影像学特征及相关因素分析[J]. 中国CT和MRI杂志, 2024, 22(2): 61-63. DOI: 10.3969/j.issn.1672-5131.2024.02.019.

YANG J P, DING C J, CHEN J, et al. Clinical characteristics, chest CT imaging characteristics and related factors of plastic bronchitis in children with MPP[J]. Chin J CT MRI, 2024, 22(2): 61-63. DOI: 10.3969/j.issn.1672-5131.2024.02.019.

[18]
DE BLIC J, MIDULLA F, BARBATO A, et al. Bronchoalveolar lavage in children. ERS Task Force on bronchoalveolar lavage in children. European Respiratory Society[J]. Eur Respir J, 2000, 15(1): 217-231. DOI: 10.1183/09031936.00.15121700.

PMID

[19]
中国医师协会儿童重症医师分会, 中国医师协会新生儿医师分会, 甘肃省妇幼保健院/甘肃省中心医院/甘肃省儿科临床医学研究中心, 等. 中国儿童支气管肺泡灌洗术临床实践指南(2024)[J]. 中国当代儿科杂志, 2024, 26(1): 1-13. DOI: 10.7499/j.issn.1008-8830.2308072.

Branch of Pediatric Critical Care Physicians of Chinese Medical Association, Neonatologists Branch of Chinese Medical Association, Gansu Provincial Maternal and Child Health Hospital/Gansu Provincial Central Hospital/Gansu Pediatric Clinical Medical Research Center, et al. Clinical practice guidelines for bronchoalveolar lavage in Chinese children(2024)[J]. Chin J Contemp Pediatr, 2024, 26(1): 1-13. DOI: 10.7499/j.issn.1008-8830.2308072.

[20]
ZHANG H, YANG J, ZHAO W, et al. Clinical features and risk factors of plastic bronchitis caused by refractory Mycoplasma pneumoniae pneumonia in children: a practical nomogram prediction model[J]. Eur J Pediatr, 2023, 182(3): 1239-1249. DOI: 10.1007/s00431-022-04761-9.

[21]
YANG L, ZHANG Y, SHEN C, et al. Clinical features and risk factors of plastic bronchitis caused by Mycoplasma pneumoniae pneumonia in children[J]. BMC Pulm Med, 2023, 23(1): 468. DOI: 10.1186/s12890-023-02766-0.

[22]
孙世瑜, 朱淼, 李田田, 等. 早期血液炎症指标对重症社区获得性肺炎导致呼吸衰竭患者预后的评估研究[J]. 新医学, 2024, 55(3): 198-203. DOI: 10.3969/j.issn.0253-9802.2024.03.009.

SUN S Y, ZHU M, LI T T, et al. Evaluation of early blood inflammation indicators on the prognosis of patients with severe community-acquired pneumonia[J]. J New Med, 2024, 55(3): 198-203. DOI: 10.3969/j.issn.0253-9802.2024.03.009.

[23]
ZAHOREC R. Neutrophil-to-lymphocyte ratio, past, present and future perspectives[J]. Bratisl Lek Listy, 2021, 122(7): 474-488. DOI: 10.4149/bll_2021_078.

PMID

[24]
ADRIE C, LUGOSI M, SONNEVILLE R, et al. Persistent lymphopenia is a risk factor for ICU-acquired infections and for death in ICU patients with sustained hypotension at admission[J]. Ann Intensive Care, 2017, 7(1): 30. DOI: 10.1186/s13613-017-0242-0.

[25]
DREWRY A M, SAMRA N, SKRUPKY L P, et al. Persistent lymphopenia after diagnosis of sepsis predicts mortality[J]. Shock, 2014, 42(5): 383-391. DOI: 10.1097/SHK.0000000000000234.

PMID

[26]
唐青, 赵龙, 张雯, 等. 外周血NLR、PLR和MPVLR水平对儿童难治性肺炎支原体肺炎的预测价值[J]. 国际呼吸杂志, 2024, 44(9): 1061-1066. DOI: 10.3760/cma.j.cn131368-20240428-00225.

TANG Q, ZHAO L, ZHANG W, et al. Predictive values of neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio and mean platelet volume-to-lymphocyte ratio in children with refractory Mycoplasmal pneumoniae pneumonia[J]. Int J Respir, 2024, 44(9): 1061-1066. DOI: 10.3760/cma.j.cn131368-20240428-00225.

[27]
LI D, GU H, CHEN L, et al. Neutrophil-to-lymphocyte ratio as a predictor of poor outcomes of Mycoplasma pneumoniae pneumonia[J]. Front Immunol, 2023, 14: 1302702. DOI: 10.3389/fimmu.2023.1302702.

[28]
陆泳, 陆磊娟, 李民, 等. 基于血小板参数构建肺炎支原体肺炎患儿发生塑型性支气管炎的风险预测列线图模型[J]. 实用心脑肺血管病杂志, 2024, 32(10): 52-58. DOI: 10.12114/j.issn.1008-5971.2024.00.253.

LU Y, LU L J, LI M, et al. Nomogram model for predicting the risk of plastic bronchitis in children with mycoplasma pneumoniae pneumonia based on platelet parameter[J]. Pract J Card Cereb Pneumal Vasc Dis, 2024, 32(10): 52-58. DOI: 10.12114/j.issn.1008-5971.2024.00.253.

[29]
LING Y, NING J, XU Y. Explore the predictive value of peripheral blood cell parameters in refractory Mycoplasma pneumoniae pneumonia in children over 6 years old[J]. Front Pediatr, 2021, 9: 659677. DOI: 10.3389/fped.2021.659677.

[30]
PONTI G, MACCAFERRI M, RUINI C, et al. Biomarkers associated with COVID-19 disease progression[J]. Crit Rev Clin Lab Sci, 2020, 57(6): 389-399. DOI: 10.1080/10408363.2020.1770685.

[31]
NG W W, LAM S M, YAN W W, et al. NLR, MLR, PLR and RDW to predict outcome and differentiate between viral and bacterial pneumonia in the intensive care unit[J]. Sci Rep, 2022, 12: 15974. DOI: 10.1038/s41598-022-20385-3.

[32]
ZHAO L, ZHANG T, CUI X, et al. Development and validation of a nomogram to predict plastic bronchitis in children with refractory Mycoplasma pneumoniae pneumonia[J]. BMC Pulm Med, 2022, 22(1): 253. DOI: 10.1186/s12890-022-02047-2.

[33]
SHEN F, DONG C, ZHANG T, et al. Development of a nomogram for predicting refractory Mycoplasma pneumoniae pneumonia in children[J]. Front Pediatr, 2022, 10: 813614. DOI: 10.3389/fped.2022.813614.

[34]
ZHANG J, WANG T, LI R, et al. Prediction of risk factors of bronchial mucus plugs in children with Mycoplasma pneumoniae pneumonia[J]. BMC Infect Dis, 2021, 21(1): 67. DOI: 10.1186/s12879-021-05765-w.

[35]
ZHANG X, CHEN Z, GU W, et al. Viral and bacterial co-infection in hospitalised children with refractory Mycoplasma pneumoniae pneumonia[J]. Epidemiol Infect, 2018, 146(11): 1384-1388. DOI: 10.1017/S0950268818000778.

[36]
CHEN Q, LIN L, ZHANG N, et al. Adenovirus and Mycoplasma pneumoniae co-infection as a risk factor for severe community-acquired pneumonia in children[J]. Front Pediatr, 2024, 12: 1337786. DOI: 10.3389/fped.2024.1337786.

[37]
YANG S, LU S, GUO Y, et al. A comparative study of general and severe Mycoplasma pneumoniae pneumonia in children[J]. BMC Infect Dis, 2024, 24(1): 449. DOI: 10.1186/s12879-024-09340-x.

文章导航

/